Australia scientists develop ‘world first’ melanoma blood test


Team Udayavani, Jul 18, 2018, 12:12 PM IST

Sydney: Australian researchers today said they have developed a blood test for melanoma in its early stages, calling it a “world first” breakthrough that could save many lives. The scientists, from Edith Cowan University, said the new test could help doctors detect the skin cancer before it spreads through a person’s body.

“Patients who have their melanoma detected in its early stage have a five-year survival rate between 90 and 99 per cent,” lead researcher Pauline Zaenker said in a statement. She added that survival rates fell to less than 50 per cent if the cancer spread in the body.

“This is what makes this blood test so exciting as a potential screening tool because it can pick up melanoma in its very early stages when it is still treatable,” Zaenker said.

The research, published in the journal Oncotarget today, included a trial involving 105 patients with melanoma and 104 healthy people.

The procedure detected early stage melanoma in 79 per cent of cases, the scientists said. Melanoma is currently detected using a visual scan by a doctor, with areas of concern cut out surgically and biopsied. Zaenker said the new process involved identifying autoantibodies a person’s body produces in response to the cancer.

“We examined a total of 1627 different types of antibodies to identify a combination of 10 antibodies that best indicated the presence of melanoma in confirmed patients relative to healthy volunteers,” she added.

Cancer Council Australia chief executive Sanchia Aranda said the test would be important for high-risk groups, who have to undergo regular inspections of their spots and moles that can be difficult and time-consuming.

She cautioned that the test did not pick up other types of less deadly, but more common, skin cancers such as squamous cell and basal cell carcinoma. “People need to be very aware of whether they’ve got sun damage or UV damage on their skin, and be alert to changes in any spots or moles,” she told AFP.

The scientists will conduct another clinical trial lasting three years to validate the findings, and hope to have a test that clinics can use after that. One in every three cancers diagnosed is a skin cancer, according to the World Health Organisation, with Australia having among the highest incidences of melanoma in the world.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Siddaramaiah will resign as CM before Belagavi assembly session, claims BJP’s Vijayendra

Champions Trophy: ICC puts PCB’s ‘PoK’ tour on hold after BCCI’s strong objection

Suriya-starrer ‘Kanguva’ mints Rs 58.62 crore in worldwide gross on day one

Mangaluru: Car catches fire near Kadri Police Station

J-K: 2 teenage boys driving SUV die in road accident; sparks calls to curb underage driving

Forest department creating hurdles in development of Gadchiroli district: Gadkari

700 kg drugs seized, 8 Iranians caught in anti-narcotics operation along Gujarat coast

Related Articles More

World Diabetes Day 2024: Kasturba Hospital Manipal Hosts Zumba Session at Malpe Beach to Raise Diabetes Awareness

World Diabetes Day: An overview of types of diabetes

World Diabetes Day: One-fourth of people living with diabetes in 2022 are in India, Lancet study estimates

Disruption in liver-brain communication behind overeating, Study claims

Acute Blood Shortage at Kasturba Hospital, Manipal: Donate blood and save lives

MUST WATCH

| ₹50 LAKH SEIZED FROM TIRE |

New Technology In Kambala

Lakshdeepotsava 2024 Shree Krishna Mutt

Punganur Cow

Rangoli design


Latest Additions

Siddaramaiah will resign as CM before Belagavi assembly session, claims BJP’s Vijayendra

Mangaluru: 3 key suspects in cyber fraud cases arrested

Yakshadhruva Patla Foundation women’s wing launched in Udupi

Champions Trophy: ICC puts PCB’s ‘PoK’ tour on hold after BCCI’s strong objection

Maharashtra: Jewellers face challenges in business as wedding season clashes with poll season

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.